Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Summit Therapeutics (SMMT) over the last 5 years, with Q3 2025 value amounting to $7.0 million.

  • Summit Therapeutics' Other Non-Current Assets rose 27756.31% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 27756.31%. This contributed to the annual value of $2.5 million for FY2024, which is 4104.58% down from last year.
  • Summit Therapeutics' Other Non-Current Assets amounted to $7.0 million in Q3 2025, which was up 27756.31% from $6.5 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Other Non-Current Assets ranged from a high of $7.0 million in Q3 2025 and a low of $140000.0 during Q3 2022
  • For the 5-year period, Summit Therapeutics' Other Non-Current Assets averaged around $2.3 million, with its median value being $1.9 million (2024).
  • Per our database at Business Quant, Summit Therapeutics' Other Non-Current Assets surged by 299428.57% in 2023 and then plummeted by 5699.45% in 2024.
  • Over the past 5 years, Summit Therapeutics' Other Non-Current Assets (Quarter) stood at $170000.0 in 2021, then surged by 239.41% to $577000.0 in 2022, then soared by 649.05% to $4.3 million in 2023, then tumbled by 41.05% to $2.5 million in 2024, then surged by 176.06% to $7.0 million in 2025.
  • Its Other Non-Current Assets was $7.0 million in Q3 2025, compared to $6.5 million in Q2 2025 and $4.1 million in Q1 2025.